Core Points - Broadwood Partners, L.P. and its affiliates have commented on STAAR Surgical Company's recent filing with the SEC regarding a supplement to its definitive proxy statement related to the proposed acquisition by Alcon Inc. [1] Company Summary - Broadwood Partners owns 27.5% of STAAR Surgical Company [1]

Group 1 - Broadwood Partners, L.P. and its affiliates own 27.5% of STAAR Surgical Company's outstanding common shares [1] - Broadwood is urging fellow shareholders to vote against the proposed acquisition of STAAR by Alcon Inc. [1] - The acquisition terms were announced on August 5, 2025 [1]

Core Viewpoint - STAAR Surgical Company strongly disagrees with the recommendation issued by Glass, Lewis & Co. regarding its pending merger with Alcon [1] Company Summary - STAAR Surgical is a global leader in phakic IOLs, specifically with its EVO family of Implantable Collamer® Lenses for vision correction [1] - The company is currently involved in a merger process with Alcon, a significant player in the eye care industry [1]

Core Points - Broadwood Partners and its affiliates announced that Glass Lewis, a prominent proxy advisory firm, recommended STAAR Surgical Company shareholders vote "AGAINST" the proposed acquisition by Alcon Inc. [1] Group 1 - Glass Lewis's recommendation highlights concerns regarding the acquisition terms announced on August 5, 2025 [1]

Core Viewpoint - Defender Capital opposes the proposed acquisition of STAAR Surgical Company by Alcon Inc., arguing that the offer of $28 per share significantly undervalues STAAR, especially in light of a previous offer of $58 per share that was rejected by the STAAR Board of Directors just sixteen months ago [1]. Group 1 - Defender Capital has been a significant shareholder of STAAR for over ten years and believes in the substantial value of the company [1]. - The recent positive projections and outlook from STAAR's management provide no compelling reason to sell the company at the proposed valuation [2]. - Defender Capital expresses disappointment that the STAAR Board is pursuing a transaction that does not reflect the standalone business prospects of STAAR [2].

Core Viewpoint - STAAR Surgical Company is recognized by independent industry analysts as having a favorable merger with Alcon, which offers compelling cash value for STAAR stockholders [1] Company Summary - STAAR Surgical Company is a global leader in phakic IOLs, specifically with its EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction [1] - The merger with Alcon is viewed as the best path forward for STAAR stockholders, providing a certain and premium cash value [1] Industry Summary - The commentary from independent analysts highlights the positive outlook for STAAR's stockholders following the merger with Alcon [1]

Core Viewpoint - Broadwood Partners, L.P. and its affiliates, holding approximately 27.5% of STAAR Surgical Company's outstanding common stock, are urging stockholders to vote against the proposed acquisition by Alcon Inc. on the terms announced on August 5, 2025 [1]. Group 1 - Broadwood has published a presentation to support its position against the acquisition [1]. - The acquisition is being contested on the basis of the terms outlined in the announcement made on August 5, 2025 [1].

Core Viewpoint - Alcon has successfully completed the waiting period for its acquisition of STAAR Surgical Company under the Hart-Scott-Rodino Antitrust Improvements Act, indicating progress in the acquisition process [1] Company Summary - Alcon is recognized as a global leader in eye care, focusing on enhancing vision for individuals [1] - STAAR Surgical Company is known for manufacturing the Implantable Collamer® Lens (ICL), a significant product in the eye care industry [1] Regulatory Summary - The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired at 11:59 p.m. ET on September 29, 2025, allowing Alcon to move forward with the acquisition of STAAR [1]

Core Insights - Albert Anthony is a Croatian-American business author and media contributor with a focus on real estate investment trusts (REITs) [1] - He has a background in IT analysis for Fortune 500 companies and experience in financial services with Charles Schwab [1] - Anthony is launching a book on REITs in 2025 and operates his own equities research firm remotely [1] Background and Experience - The author has over 1,000 followers on Seeking Alpha and writes for various financial platforms [1] - He has participated in numerous business and innovation conferences in the EU and the US [1] - Anthony is pursuing a CMSA certification from the Corporate Finance Institute [1] Media and Digital Presence - He is active in digital media, including a YouTube channel focused on REITs [1] - The author has appeared in regional media channels in Croatia and has experience in casting agencies [1] - He does not engage with non-publicly traded companies or small-cap stocks [1]

Core Insights - Albert Anthony is a Croatian-American business author and media contributor with a focus on real estate investment trusts (REITs) [1] - He has a background in IT analysis for Fortune 500 companies and experience in financial services with Charles Schwab [1] - Anthony is launching a book on REITs in 2025 and manages his own equities research firm remotely [1] Background and Experience - The author has over 1,000 followers on Seeking Alpha and writes for various financial platforms [1] - He has participated in numerous business and innovation conferences in the EU and has a degree from Drew University [1] - Currently enrolled in the CMSA certification program at the Corporate Finance Institute in Vancouver [1] Media and Digital Presence - Albert Anthony is active in digital media, including a YouTube channel focused on REITs [1] - He has appeared in regional media channels in Croatia and has had roles in over five productions [1] - The author does not engage with non-publicly traded companies or small-cap stocks [1]